Log In
Print this Print this

Abasaglar, Basaglar, insulin glargine (LY2963016) (formerly Abasria)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionBasal insulin analog
Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type I and II diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation U.S. - Undisclosed Review (Treat Type I and II diabetes);
EU - Biosimilar (Treat Type I and II diabetes);
EU - Standard Review (Treat Type I and II diabetes)
PartnerBoehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today